Treatment of hyperlipidemia in women
Article Abstract:
Cholesterol lowering may reduce deaths among women with coronary heart disease (CHD), but cholesterol lowering in healthy women does not appear to reduce coronary artery disease or mortality. Researchers studied the effects of cholesterol lowering on prevention of CHD and regression of coronary atherosclerosis by reviewing medical literature. Cholesterol lowering may decrease deaths from CHD by 15%. For women with CHD who are treated with the drug lovastatin and have cholesterol levels of 6.47 micromoles per liter of blood, the annual cost of life saved is between $3,500 and $15,000. Women with elevated cholesterol should be treated and those with CHD should be tested for hyperlipidemia, which is an elevated concentration of lipids in the blood.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Drug treatment of hyperlipidemia in women
Article Abstract:
Coronary disease is the leading factor of death that occurs in women in the United States. The reasons for the cause of coronary heart disease are discussed.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Drug treatment of hyperlipidemia in women
Article Abstract:
Coronary disease is the leading factor of death that occurs in women in the United States. The reasons for the cause of Coronary heart disease are discussed.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
- Abstracts: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
- Abstracts: Reinvention of health insurance in the consumer era. Influence of the HIPAA privacy rule on health research. Market justice and US health care
- Abstracts: Prevalence of chlamydial and gonococcal infections amog young adults in the United States